Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BHR
3051
Braemar Hotels & Resorts
BHR
$83.1M
| $293K | ﹤0.01% |
102,409
-622,800
| -86% | -$1.81M |
2015 Q1
21 quarters
|
|
|
AKTX
3052
Akari Therapeutics
AKTX
$20M
| $291K | ﹤0.01% |
167
+5
| +3% | +$7.62K |
2019 Q1
5 quarters
|
|
3053
Eledon Pharmaceuticals
ELDN
$202M
| $291K | ﹤0.01% |
35,293
+9,886
| +39% | +$112K |
2015 Q4
18 quarters
|
|
|
HOOK
3054
DELISTED
HOOKIPA Pharma
HOOK
| $290K | ﹤0.01% |
+2,492
| New | +$243K |
2020 Q2
0 quarters
|
|
|
PRPH
3055
DELISTED
ProPhase Labs
PRPH
| $289K | ﹤0.01% |
20,070
+580
| +3% | +$9.61K |
2013 Q2
28 quarters
|
|
|
BHAT
3056
DELISTED
Blue Hat Interactive Entertainment Technology
BHAT
| $288K | ﹤0.01% |
+4
| New | +$217K |
2020 Q1
1 quarter
|
|
|
ETTX
3057
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $288K | ﹤0.01% |
97,446
+62,343
| +178% | +$170K |
2019 Q3
3 quarters
|
|
3058
iShares S&P 100 ETF
OEF
$20.8B
| $285K | ﹤0.01% |
+2,000
| New | +$269K |
2020 Q2
0 quarters
|
|
|
CALB
3059
DELISTED
California BanCorp Common Stock
CALB
| $285K | ﹤0.01% |
+19,100
| New | +$277K |
2020 Q2
0 quarters
|
|
3060
Loop Industries
LOOP
$20.3M
| $284K | ﹤0.01% |
+31,600
| New | +$271K |
2020 Q2
0 quarters
|
|
|
PSTL
3061
Postal Realty Trust
PSTL
$688M
| $283K | ﹤0.01% |
+17,750
| New | +$280K |
2020 Q2
0 quarters
|
|
|
NTRP
3062
DELISTED
Neurotrope, Inc. Common
NTRP
| $283K | ﹤0.01% |
244,196
+228,886
| +1,495% | +$287K |
2020 Q1
1 quarter
|
|
3063
Metallus
MTUS
$829M
| $281K | ﹤0.01% |
72,146
+48,746
| +208% | +$163K |
2020 Q1
1 quarter
|
|
|
UFAB
3064
DELISTED
Unique Fabricating, Inc.
UFAB
| $281K | ﹤0.01% |
88,177
+5,557
| +7% | +$17.3K |
2018 Q1
9 quarters
|
|
3065
Xeris Biopharma Holdings
XERS
$1.91B
| $279K | ﹤0.01% |
105,000
-282,516
| -73% | -$984K |
2020 Q1
1 quarter
|
|
3066
CPS Technologies
CPSH
$68.6M
| $278K | ﹤0.01% |
+115,000
| New | +$154K |
2020 Q2
0 quarters
|
|
|
FFWM
3067
DELISTED
First Foundation Inc
FFWM
| $276K | ﹤0.01% |
16,900
-146,065
| -90% | -$1.96M |
2016 Q4
14 quarters
|
|
3068
Richmond Mutual Bancorp
RMBI
$246M
| $276K | ﹤0.01% |
24,542
+5,033
| +26% | +$53.2K |
2020 Q1
1 quarter
|
|
3069
Liberty Media Corporation Series C Common Stock
FWONK
$23.6B
| $275K | ﹤0.01% |
8,977
-283,613
| -97% | -$8.42M |
2019 Q4
2 quarters
|
|
3070
Direxion Daily Regional Banks Bull 3X ETF
DPST
$308M
| $274K | ﹤0.01% |
+2,250
| New | +$283K |
2020 Q2
0 quarters
|
|
3071
State Street SPDR S&P Dividend ETF
SDY
$20.7B
| $274K | ﹤0.01% |
+3,000
| New | +$264K |
2020 Q2
0 quarters
|
|
|
ELOX
3072
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $274K | ﹤0.01% |
2,258
-1,012
| -31% | -$115K |
2019 Q3
3 quarters
|
|
3073
Lifetime Brands
LCUT
$219M
| $272K | ﹤0.01% |
40,500
-17,300
| -30% | -$92.8K |
2013 Q4
26 quarters
|
|
3074
SIFCO Industries
SIF
$149M
| $272K | ﹤0.01% |
68,034
+1,400
| +2% | +$4.72K |
2013 Q2
28 quarters
|
|
3075
Vanguard S&P 500 Value ETF
VOOV
$6.68B
| $272K | ﹤0.01% |
+2,600
| New | +$267K |
2020 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.